These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 27578134)

  • 1. Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia.
    Duell PB; Santos RD; Kirwan BA; Witztum JL; Tsimikas S; Kastelein JJP
    J Clin Lipidol; 2016; 10(4):1011-1021. PubMed ID: 27578134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
    Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
    J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Target achievement and cardiovascular event rates with Lomitapide in homozygous Familial Hypercholesterolaemia.
    Blom DJ; Cuchel M; Ager M; Phillips H
    Orphanet J Rare Dis; 2018 Jun; 13(1):96. PubMed ID: 29925433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials.
    Santos RD; Raal FJ; Catapano AL; Witztum JL; Steinhagen-Thiessen E; Tsimikas S
    Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):689-99. PubMed ID: 25614280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease.
    Stein EA; Dufour R; Gagne C; Gaudet D; East C; Donovan JM; Chin W; Tribble DL; McGowan M
    Circulation; 2012 Nov; 126(19):2283-92. PubMed ID: 23060426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.
    Raal FJ; Santos RD; Blom DJ; Marais AD; Charng MJ; Cromwell WC; Lachmann RH; Gaudet D; Tan JL; Chasan-Taber S; Tribble DL; Flaim JD; Crooke ST
    Lancet; 2010 Mar; 375(9719):998-1006. PubMed ID: 20227758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia.
    Raal FJ; Braamskamp MJ; Selvey SL; Sensinger CH; Kastelein JJ
    J Clin Lipidol; 2016; 10(4):860-869. PubMed ID: 27578117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential of mipomersen, an ApoB synthesis inhibitor, to reduce necessity for LDL-apheresis in patients with heterozygous familial hypercholesterolemia and coronary artery disease.
    Vogt A; Parhofer KG
    Expert Opin Pharmacother; 2013 Apr; 14(6):691-7. PubMed ID: 23477485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic potential of mipomersen in the management of familial hypercholesterolaemia.
    Gelsinger C; Steinhagen-Thiessen E; Kassner U
    Drugs; 2012 Jul; 72(11):1445-55. PubMed ID: 22799743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mipomersen, an antisense apolipoprotein B synthesis inhibitor.
    Bell DA; Hooper AJ; Burnett JR
    Expert Opin Investig Drugs; 2011 Feb; 20(2):265-72. PubMed ID: 21210756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mipomersen sodium: a new option for the treatment of familial hypercholesterolemia.
    Haddley K
    Drugs Today (Barc); 2011 Dec; 47(12):891-901. PubMed ID: 22348914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia.
    Reeskamp LF; Kastelein JJP; Moriarty PM; Duell PB; Catapano AL; Santos RD; Ballantyne CM
    Atherosclerosis; 2019 Jan; 280():109-117. PubMed ID: 30500603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension.
    Santos RD; Duell PB; East C; Guyton JR; Moriarty PM; Chin W; Mittleman RS
    Eur Heart J; 2015 Mar; 36(9):566-75. PubMed ID: 24366918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging LDL therapies: Mipomersen-antisense oligonucleotide therapy in the management of hypercholesterolemia.
    Toth PP
    J Clin Lipidol; 2013; 7(3 Suppl):S6-10. PubMed ID: 23642326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
    Avellone G; Di Garbo V; Guarnotta V; Scaglione R; Parrinello G; Purpura L; Torres D; Campisi D
    Int Angiol; 2010 Dec; 29(6):514-24. PubMed ID: 21173733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is mipomersen ready for clinical implementation? A transatlantic dilemma.
    Sjouke B; Balak DM; Beuers U; Ratziu V; Stroes ES
    Curr Opin Lipidol; 2013 Aug; 24(4):301-6. PubMed ID: 23759796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New pharmacologic treatments for familial hypercholesterolemia.
    McDonough A; Matura LA; Carroll D
    Nurs Womens Health; 2013 Oct; 17(5):443-7. PubMed ID: 24138664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia.
    Akdim F; Visser ME; Tribble DL; Baker BF; Stroes ES; Yu R; Flaim JD; Su J; Stein EA; Kastelein JJ
    Am J Cardiol; 2010 May; 105(10):1413-9. PubMed ID: 20451687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein B antisense inhibition--update on mipomersen.
    Gebhard C; Huard G; Kritikou EA; Tardif JC
    Curr Pharm Des; 2013; 19(17):3132-42. PubMed ID: 23317401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis.
    Leipold R; Raal F; Ishak J; Hovingh K; Phillips H
    Eur J Prev Cardiol; 2017 Nov; 24(17):1843-1850. PubMed ID: 28925748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.